About
The activity of membrane transporters critically determines clinical drug response and is a key factor of the respective interindividual variability and the onset of drug-drug interactions. Their expression is largely controlled by nuclear receptors whose activities are modulated by ligand binding of small molecules and which are thus predestinated therapeutic drug targets. By using compound library screening, molecular cell biology and –omics technologies, as well as state-of-the-art mouse models and patient cohorts, we aim to unravel the role of membrane transporters and nuclear receptors in metabolic liver diseases and cancer and explore their potential as novel drug targets.